glucocorticoid-induced osteoporosis (GIOP)
Conditions
Interventions
Denosumab
alendronate
Sponsors
Saitama Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with GIOP who have done full teriparatide therapy
Exclusion criteria
Exclusion criteria: 1)Patients who have serious renal disorder (eGFR<35ml/min or Cr>1.5mg/ml) 2)Patient who has a history of renal stone past 5 years 3)Patients with primary or secondary hyperparathyroidism 4)Patients with hyperthyroidism or hypothyroidism 5)Patients who are considered to be contraindicated for bisphosphonates or denosumab 6)Patients who are treated with warfarin or digitalis 7)Patients who have newly received drugs having influence on bone remodeling within 6 months at inclusion of the study (estriol, estradiol, Vitamin D3, Vitamin K2, SERM(Raloxifene, bazedoxifene), Calcitonin, Ipriflavone, Steroids) 8)Patients who had received bisphosphonates during teriparatide therapy 9) Patients who are thought to be inappropriate for this study by physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Symptomatic vertebral fractures, those are determined by conventional thoracic and spinal radiographs in lateral and antero-posterior projections at any time during 3 years of this study. | — |
Secondary
| Measure | Time frame |
|---|---|
| Non symptomatic vertebral fractures and non-vertebral fractures deetermined by plain X-ray. Bone mineral density values, those are measured at the lumbar spine. The serum levels of NTX, osteocalcin, 25(OH)vitamin D, etc. | — |
Countries
Japan
Contacts
Public ContactHirofumi Takei
Saitama Medical Center, Saitama Medical Universitity Department of Rheumatology & Clinical Immunology
Outcome results
None listed